The Advent of Subsequent Entry Biologics: Biosimilars in Canada


Whether or not you are involved with a biologic product, continuing education in this fascinating and growing field in Canadian Healthcare is an opportunity for your professional development. Subsequent Entry Biologicals (SEBs or “biosimilars”) will represent an increasing proportion of the bio-pharmaceutical marketplace. The path to market for these agents is different than that of generic, small molecule drugs. This course is designed to help you better understand the world of biologicals and SEBs.


After completing the course, students will be able to:

  • Describe the complexity of biologics vs small molecule drugs
  • Discuss the general manufacturing process for Biologicals and Biosimilars
  • Discuss the definitions of biosimilarity, bioequivalence, interchangeability, and substitution and Health Canada’s position on and requirements for SEBs


  • 50 multiple choice questions

Course Features

  • Suggested Hours of Study 11
  • Quizzes 0
  • Suggested Hours of Study 26 hrs
  • Course Completion 6 months
  • Course Format Paper
  • RxTx No
  • Language English
  • Pages 255 pages
  • C.E. Credits What is this? 2.6
  • Orientation Package

Exam Details

  • # of Questions 50
  • Time Limit 1 hr
  • Passing Grade 60%


  • Price $1,138.00
  • Corporate Member $569.00
  • Corporate Non-Member $2,845.00